Strategic Growth M&A and collaboration opportunities with complementary diagnostics or pharma services players, given Wren’s recent Pure Diagnostic acquisition and expansion of neuroendocrine and prostate cancer testing.

Clinical Validation Leverage Wren’s extensive clinical validation and CLIA/CAP/NYSDOH accreditation to position readiness for deployment in hospital systems, translational research, and multi-site clinical trials.

Therapeutic Alignment Target biopharma and CDx development teams to offer AI/ML liquid biopsy genomic assays and companion diagnostics that align with precision oncology programs and regulatory submissions.

Global Expansion Capitalize on Asia neuroendocrine tumor testing expansion and ongoing international testing menu development to pursue regional collaborations, distribution partnerships, and CRO engagements.

Trial Operations Promote RNA stabilizer tubes and ambient-temperature logistics as a value-add for clinical trial supply chains, potentially reducing shipping constraints and improving specimen integrity.